A LinkedIn post from HistoSonics highlights the company’s presence at the Society of Surgical Oncology (SSO) meeting in Phoenix and promotes a breakfast symposium on histotripsy. The session, titled “Histotripsy in Practice: Real-World Experience, Evidence, and Future Frontiers,” is scheduled for March 6 from 7:00 a.m. to 7:45 a.m. with breakfast beginning at 6:45 a.m.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the symposium will feature surgical oncologists from MD Anderson Cancer Center at Cooper and Northeast Georgia Medical Center discussing the transition of histotripsy from innovation to clinical implementation. HistoSonics also points to its Edison Histotripsy System, noting that its team will be available for discussions at booth 821 on the exhibition floor.
The post suggests that HistoSonics is emphasizing clinical adoption and evidence generation around its histotripsy technology, particularly in liver applications where the Edison System is currently focused. Visible engagement with leading cancer centers may support the company’s positioning as a differentiated player in noninvasive tumor treatment, which could be important for future reimbursement, partnership, and commercialization prospects.
The disclaimer that Edison’s use outside liver applications is limited to clinical investigations underscores the early-stage regulatory and commercialization status of broader indications. For investors, ongoing clinical experience, physician education, and specialty-society visibility at events such as SSO may be key leading indicators of eventual procedure volume growth, market acceptance, and potential valuation inflection if pivotal data and regulatory milestones are achieved.